Rapport Therapeutics, Inc.
Rapport Therapeutics is a clinical-stage biotechnology company headquartered in Boston, Massachusetts. It discovers and develops small molecule precision medicines for patients with neurological or psychiatric disorders, using a receptor associated protein technology platform to target neuronal receptor complexes. Rapport’s most advanced product candidate, RAP-219, is being evaluated for focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. The company is also developing a long-acting injectable formulation of RAP-219. Its discovery-stage programs include RAP-641, a candidate for chronic pain and migraine, and a program focused on potential therapies for hearing and vestibular disorders. Rapport has exclusive global rights to use its technology platform and commercialize its product candidates.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Stifel maintained a Buy rating and $56 price target for Rapport Therapeutics (RAPP) after its Q3 2026 earnings. The stock is at $25.83, up 13% in a week but down 28% in six months. Positive phase 2 data for RAP-219 in bipolar mania and ongoing phase 3 epilepsy trials were noted. Other analysts have adjusted price targets, ranging from $50 to $82, reflecting mixed but generally optimistic views.
Raymond James cut its price target for Rapport Therapeutics (RAPP) to $73 from $86, citing underwhelming bipolar mania data. The stock is down 50% from its 52-week high but gained 13% recently. Analysts highlight FOS as the primary valuation driver. Other firms like Jones Trading and Guggenheim raised targets, while Wells Fargo lowered its target slightly. RAPP trades at $26.23.
Rapport Therapeutics reported a Q3 2026 net loss of $40.2M, up from $26.9M a year earlier, due to increased R&D spending. The company had $395M in cash at Q3's end and expects $815.4M in liquidity by November 3. RAP-219 showed positive Phase 2 results for bipolar mania, with Phase 3 trials planned. The company also advanced its pipeline with other trials and FDA clearances.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning RAPP (Rapport Therapeutics, Inc.). Coverage has skewed bearish: 2 bullish, 1 neutral, and 4 bearish.
Recent RAPP coverage spans earnings, corporate actions and financial news.
In the last 30 days, RAPP insiders filed 12 SEC Form 4 transactions — 11 purchases ($22.0M) and 1 sale ($64K). The most active reporter was HEALY JAMES with 4 filings. 8% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst upgrade suggests upside potential.
Analyst price target cut suggests weaker outlook for the stock.
The loss widens but the Phase 2 success may lift sentiment, especially for the bipolar mania indication.
Positive trial data and fresh capital likely boost RAPP share price.
The sizable equity raise dilutes existing shareholders but extends the cash runway, likely causing short‑term price pressure.
AlphAI scores every news story that mentions RAPP with an AI model for sentiment and relevance, and aggregates insider trades from Rapport Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Stifel maintained a Buy rating and $56 price target for Rapport Therapeutics (RAPP) after its Q3 2026 earnings. The stock is at $25.83, up 13% in a week but down 28% in six months. Positive phase 2 data for RAP-219 in bipolar mania and ongoing phase 3 epilepsy trials were noted. Other analysts have adjusted price targets, ranging from $50 to $82, reflecting mixed but generally optimistic views.
Raymond James cut its price target for Rapport Therapeutics (RAPP) to $73 from $86, citing underwhelming bipolar mania data. The stock is down 50% from its 52-week high but gained 13% recently. Analysts highlight FOS as the primary valuation driver. Other firms like Jones Trading and Guggenheim raised targets, while Wells Fargo lowered its target slightly. RAPP trades at $26.23.
Rapport Therapeutics reported a Q3 2026 net loss of $40.2M, up from $26.9M a year earlier, due to increased R&D spending. The company had $395M in cash at Q3's end and expects $815.4M in liquidity by November 3. RAP-219 showed positive Phase 2 results for bipolar mania, with Phase 3 trials planned. The company also advanced its pipeline with other trials and FDA clearances.
Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label
Rapport Therapeutics (RAPP) closed public offerings of 9.76M shares, raising $411M. Proceeds will fund clinical trials, R&D, and operations through 2029. The company may also use funds for acquisitions or investments. Morgan Stanley, Leerink Partners, and Evercore ISI led the offerings.
HEALY JAMES purchased 969,480 indirectly-held shares of Rapport Therapeutics, Inc. (RAPP) at $21.00 ($20.36M total) across 4 trades on 2026-10-28.
Rapport Therapeutics (RAPP) raised over $400M through stock, notes, and private placement offerings on Oct 30, 2026. The company secured $215.7M from a stock offering at $21 per share, $166.8M from convertible notes, and $30M from a private placement. Proceeds will support clinical trials, R&D, and general corporate purposes.
Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 1.01 Entry into a Material Definitive Agreement. Underwriting Agreement in Respect of Common Stock and Pre-Funded Warrants On October 28, 2026, Rapport Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Equity Underwriting Agreement”) with Morgan
Rapport Therapeutics (RAPP) shares dropped 20% in after-hours trading after announcing a $200M common stock offering and $150M convertible notes offering. Proceeds will fund clinical trials, R&D, and potential acquisitions. The company's market cap is $1.32B, with shares down 4.9% over the past year.
Rapport Therapeutics (NASDAQ: RAPP) announced positive Phase II trial results for RAP-219 in bipolar mania, with plans to advance to Phase III. The drug was well-tolerated, with mild to moderate adverse events. The company aims to meet with the FDA in Q1 2027 and start Phase III trials in the second half of 2027. Rapport also expects to report long-term safety data for RAP-219 in focal onset seizures in Q4 2026.
